logo
Plus   Neg
Share
Email

Pfizer To Collaborate On IGNITE's Research Program On Novel Vaccinia Viruses

IGNITE Immunotherapy Inc., a new company focused on oncolytic virus vaccine design, discovery and development announced its formation.

IGNITE said that along with strategic collaborative partner and lead investor Pfizer Inc. (PFE), it will focus on the discovery and development of targeted and proprietary next-generation intravenous oncolytic (cancer cell lysing) virus vaccines for the immunotherapy of cancer. These biotherapeutics may be optimized for use in combination with immune checkpoint inhibitors.

IGNITE is developing a robust and proprietary vector discovery platform, Oncolytic Vaccine Evolution, to potentially discover novel vectors for use in its lytic cancer vaccine products.

As per the deal, Pfizer will hold a 50 percent equity investment in IGNITE. Pfizer will provide full research and development funding for three years, and Pfizer has exclusive option to acquire IGNITE after initial research program is completed. Pfizer also has two seats on IGNITE's board of directors. Financial terms were not disclosed.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Inc. (WMT) reported adjusted EPS of $1.41 for the fourth-quarter of fiscal 2019. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $1.33 for the quarter. Analysts' estimates typically exclude special items. Net income attributable to Walmart... Anglo-Australian miner BHP, formerly known as BHP Billiton, reported Tuesday higher attributable profit in its first half, while revenues were flat. Underlying EBITDA margin was lower. Further, the company maintained its dividend. Looking ahead, the company said its productivity for the 2019 financial year is now expected to be broadly flat. Asia-focused lender HSBC Holdings Plc reported Tuesday higher profit in its fiscal 2018 reflecting revenue growth in all of global businesses, despite a challenging fourth quarter. Further, the company said it reported a good start to 2019, noting that Group revenue performance in January was ahead of plan for the month. In London, HSBC shares were losing around 4 percent in the morning trading.
Follow RTT